MagForce (DB: MF6)

Last close As at 22/02/2024

0.02

0.01 (100.00%)

Market capitalisation

Edison Investment Research is terminating coverage on MagForce. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | QuickView

MagForce — Primed to execute on its growth strategy

Healthcare | Update

MagForce — Primed to execute on its growth strategy

Healthcare | Update

MagForce — Time to capitalise on growth potential

Healthcare | Update

MagForce — NanoTherm on track for US approval in 2021

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (73.9) (99.0) (99.5)
Relative (75.2) (99.0) (99.4)
52 week high/low €3.6/€0.0

Financials

MagForce is a German med-tech firm with a CE-mark approved nanotechnology cancer treatment. This consists of NanoTherm (iron nanoparticles), Nanoplan (software) and NanoActivator (a device that produces a powerful magnetic field to heat the nanoparticles, which destroys or sensitises tumour cells to therapy).

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2020A 0.6 19.3 (9.7) (0.35) N/A N/A
2021A 0.4 (6.1) (8.9) (0.30) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

edison tv

Healthcare

Executive interview – Magforce at EKF 2019

Update

Healthcare

MagForce — The land of opportunity awaits NanoTherm

Update

Healthcare

MagForce — The land of opportunity awaits NanoTherm

Flash note

Healthcare

MagForce — US prostate cancer study progresses

Update

Healthcare

MagForce — Revenue growth is needed from EU roll-out

Update

Healthcare

MagForce — 2019 a pivotal year

Update

Healthcare

MagForce — 2019 a pivotal year

Update

Healthcare

MagForce — NO SUBTITLE

Update

Healthcare

MagForce — 2017 lays foundation for 2018 progress

Update

Healthcare

MagForce — H117: EIB funding to accelerate rollout

Update

Healthcare

MagForce — Update

Initiation

Healthcare

MagForce — Steady progress

Outlook

Healthcare

MagForce — Steady progress